Title:
腫瘍特異的細胞枯渇のための化合物及び方法
Document Type and Number:
Japanese Patent JP7225135
Kind Code:
B2
Abstract:
Described is a human IgG2 anti-CD25 antibody, wherein the antibody depletes CD25 cells, in particular tumour-infiltrating regulatory T cells. The antibody can be used in the treatment of cancer, for example in treating solid tumours and in haematological cancers.
Inventors:
Melhiels Pascal
Gouvier Anne
moulder kevin
Salim Josephine
goyentea corso beatriz
Quesada Sergio
pegs curl
Arce Vargas Frederic
Solomon Isabel
Mabbit Joseph
Hopley Stephanie
Gouvier Anne
moulder kevin
Salim Josephine
goyentea corso beatriz
Quesada Sergio
pegs curl
Arce Vargas Frederic
Solomon Isabel
Mabbit Joseph
Hopley Stephanie
Application Number:
JP2019572678A
Publication Date:
February 20, 2023
Filing Date:
July 06, 2018
Export Citation:
Assignee:
Tusk Therapeutics Limited
International Classes:
C07K16/28; A61K39/395; A61K45/00; A61P35/00; A61P35/02; A61P43/00; C07K16/46; C12N15/13
Domestic Patent References:
| JP2006523433A |
Foreign References:
| WO2014145907A1 |
Other References:
Immunity, 2017 April, Vol.46,pp.577-586
Proc. Natl. Acad. Sci.,1984, Vol.81, pp.6851-6855
Proc. Natl. Acad. Sci.,1984, Vol.81, pp.6851-6855
Attorney, Agent or Firm:
Saegusa International Patent Office
Previous Patent: Surgical instrument with firing member support
Next Patent: METHOD AND APPARATUS FOR MEASURING ELECTRIC SIGNAL
Next Patent: METHOD AND APPARATUS FOR MEASURING ELECTRIC SIGNAL